What is the official ID of this bill?

The official print number for this legislation is HR 5331.

When did the legislative process begin?

The process officially started on 2021-09-22.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/117/bills/hr5331/BILLS-117hr5331ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

Who is the primary sponsor?

The primary sponsor is Rep. Davis, Danny K. [D-IL-7].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Analysis and Potential Impact of HR 5331

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Improved Access to Innovative Medical Devices for Kidney Disease Patients

Q: What are the main provisions?

Key points include: Establishes a temporary, three-year add-on payment for new FDA-approved medical devices used in the diagnosis, treatment, or management of end-stage renal disease (ESRD). Aims to increase the availability of innovative technologies for Medicare patients with ESRD, potentially improving their treatment and reducing healthcare costs. The additional payments are designed to incentivize the adoption and use of newer devices that could shorten hospital stays and improve patient outcomes.

This act aims to enhance access to new, innovative medical devices for individuals with end-stage renal disease (ESRD) covered by Medicare. It introduces temporary, additional payments for healthcare providers, encouraging the use of newer technologies in diagnosing and treating this condition. As a result, patients may benefit from more modern treatment methods, potentially improving their quality of life and reducing hospitalizations.

Key points

Establishes a temporary, three-year add-on payment for new FDA-approved medical devices used in the diagnosis, treatment, or management of end-stage renal disease (ESRD).

Aims to increase the availability of innovative technologies for Medicare patients with ESRD, potentially improving their treatment and reducing healthcare costs.

The additional payments are designed to incentivize the adoption and use of newer devices that could shorten hospital stays and improve patient outcomes.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Patient Access to ESRD New Innovative Devices Act

Print number: HR 5331

Sponsor: Rep. Davis, Danny K. [D-IL-7]

Process start date: 2021-09-22

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash

Source data: api.congress.gov

AI work logs for this document launch

Improved Access to Innovative Medical Devices for Kidney Disease Patients

Key Questions about Improved Access to Innovative Medical Devices for Kidney Disease Patients